ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
- Conditions
- Mesothelioma
- Registration Number
- NCT00040625
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- All
- Target Recruitment
- Not specified
- Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
- Prior chemotherapy for your disease is allowed
- Measurable lesion is not required
- Have a adequate performance status
- Sign an informed consent form
- You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
- You are excluded from this trial if you have received radiation within the previous 2 weeks
- You are excluded from this trial if you are a candidates for curative surgery
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
🇺🇸Basking Ridge, New Jersey, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
🇸🇦Jeddah, Saudi Arabia
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician."
🇪🇬Cairo, Egypt